Nightingale Health Plc | Press Release | June 16, 2025 at 09:35:00 EEST

South Savo Wellbeing Services County and Nightingale Health have agreed to pilot Nightingale Health’s blood analysis technology as part of the wellbeing services county’s primary healthcare. As a result of this collaboration, Nightingale Health’s disease risk detection test will be made available to over 100,000 people.

“To our knowledge, this is the first initiative in the world where a public healthcare system is applying innovative ‘omics technology to implement preventative primary healthcare. With this pioneering initiative we are creating a groundbreaking example of how the most pressing problem in healthcare can be managed by effectively preventing chronic diseases. A preventative healthcare system made possible by Nightingale Health yields better results at lower costs and adds more healthy years for people in their lives,” says Teemu Suna, CEO and Founder of Nightingale Health.

“South Savo Wellbeing Services County wants to be a forerunner in preventative healthcare. We must discover new innovations to be able to adapt to the future. The population is aging, the demand for services is growing and a large part of the personnel is reaching retirement age. I hope that we can lead by example for Finland and for an aging Europe,” says Santeri Seppälä, County Chief Executive Officer of South Savo Wellbeing Services County.

The core principle of preventative healthcare lies in the ability to detect and reduce disease risks in a healthy population to prevent the onset of diseases. The measures and tools for reducing these risks are well known. However, the most significant challenge in implementing preventative healthcare has been the ability to detect disease risks in a healthy population, as the risk assessment tools currently used in healthcare require too many resources to be applied at population level.

Nightingale Health’s globally unique blood analysis technology enables, for the first time, the comprehensive and cost-effective detection of chronic disease risks at population level. In the pilot, Nightingale Health’s technology will be used as a as a novel and comprehensive solution for preventative healthcare that can measure disease risks, target preventative interventions, and evaluate and verify the efficacy of these interventions.

The initiative involves collecting and analyzing blood samples over several years, creating nationally and internationally unique and significant data. This data will enable the reliable demonstration of outcome-based healthcare – and through this, a shift in operating models towards preventative healthcare.

The initiative will begin in August with a pre-implementation project, the aim being to start offering Nightingale Health’s test in early 2026 as part of the wellbeing services county’s services. The agreement makes it possible for two other wellbeing service counties to join the initiative during the fall. More information regarding the initiative will be communicated once the pre-implementation project has been launched.

For further information, please contact
Teemu Suna, CEO
ir@nightingalehealth.com

About Nightingale Health
Nightingale Health has developed the world's most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and it can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The Company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/

Image Attachments
Nightingale Health

Läs mer på MFN